Lytix Biopharma: Program Partner
Lytix Biopharma is a private R&D company focused on developing novel cancer immunotherapies.
The lead project- LTX315 – a first-in-class oncolytic peptide immunotherapy
LTX-315 makes ”cold tumors hot” and responsive to Immune Checkpoint Inhibitors (ICIs) by releasing an extended range of tumor specific antigens
LTX-35 may be an ideal combination partner for ICIs – potential to augment efficacy without adding significant toxicity.
It has demonstrated strong pre-clinical anticancer activity and increased efficacy with ICIs
In an ongoing phase I study LTX-315 has shown clinical evidence of anti-tumor and systemic immune effects.
– Stable disease (irRC response criteria) – in 50% of patients
– Significant infiltration of CD8+ T-cells – 75% of patients